Topical ocular anti-inflammatory agents are used to treat inflammatory eye disease to prevent which complication?

• A. Corneal Scarring
• B. Fungal Blepharitis
• C. Premature Cataracts
• D. Open-angle Glaucoma

Answer: (A)

Topical ocular anti-inflammatory agents work by dampening the inflammatory response in the eye, which protects delicate corneal tissue from damage. Inflammatory processes can trigger release of enzymes and cytokines that break down corneal collagen and alter the stromal matrix, leading to scarring that blurs or distorts vision. By inhibiting these inflammatory mediators—steroids broadly suppress inflammation and NSAIDs block prostaglandin synthesis—the drugs reduce tissue destruction and prevent scar formation on the cornea. That makes corneal scarring the most likely complication to be avoided with appropriate topical anti-inflammatory therapy.

Fungal blepharitis is an infection, not a consequence of inflammation that these agents are aimed at preventing, so anti-inflammatories don’t inherently prevent that. Premature cataracts can be a long-term adverse effect of steroid use rather than a targeted prevented outcome. Open-angle glaucoma is a separate condition related to intraocular pressure and optic nerve damage, and while steroids can raise IOP in some patients, preventing glaucoma isn’t the goal of topical anti-inflammatory therapy.